Tempest Therapeutics, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Tempest Therapeutics, Inc. (TPST) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $1.58 million as of 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-30
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.58M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.17M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $809.00K.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $576.00K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2025-12-31 | $1.58M 10-K · filed 2026-03-30 | |
| 2024-12-31 | $1.17M 10-K · filed 2026-03-30 | |
| 2023-12-31 | $809.00K 10-K · filed 2025-03-27 | |
| 2022-12-31 | $576.00K 10-K · filed 2024-03-19 | |
| 2021-12-31 | $3.78M 10-K · filed 2023-03-22 | |
| 2020-12-31 | $254.00K 10-K · filed 2022-03-29 | $4.07M 10-K · filed 2021-03-29 |
| 2019-12-31 | $4.11M 10-K · filed 2021-03-29 | |
| 2018-12-31 | $5.21M 10-K · filed 2020-03-11 | |
| 2017-12-31 | $168.00K 10-K · filed 2019-04-01 | $4.59M 10-K · filed 2018-03-15 |
| 2016-12-31 | $7.75M 10-K · filed 2018-03-15 | |
| 2015-12-31 | $6.47M 10-K · filed 2017-03-02 | |
| 2014-12-31 | $5.59M 10-K · filed 2016-02-26 | |
| 2013-12-31 | $1.60M 10-K · filed 2015-03-16 | |
| 2012-12-31 | $142.00K 10-K · filed 2014-02-27 | |
| 2011-12-31 | $22.00K 10-K · filed 2013-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |